Man Group PLC Gilead Sciences, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Man Group PLC holds 629,612 shares of GILD stock, worth $56.8 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

629,612

Previous 1,189,691 47.08%

Holding current value

$56.8 Million

Previous $81.6 Million 35.34%

% of portfolio

0.15%

Previous 0.22%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $37.3 Million - $47 Million	-560,079 Reduced 47.08%	629,612 $52.8 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $12.5 Million - $14.5 Million	198,367 Added 20.01%	1,189,691 $81.6 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $38.1 Million - $46.4 Million	531,975 Added 115.81%	991,324 $72.6 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $8.29 Million - $9.4 Million	-113,149 Reduced 19.76%	459,349 $37.2 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $39.6 Million - $43.2 Million	-536,079 Reduced 48.36%	572,498 $42.9 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $28.4 Million - $32.4 Million	-373,507 Reduced 25.2%	1,108,577 $85.4 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $63.1 Million - $71.9 Million	-816,806 Reduced 35.53%	1,482,084 $123 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $40.1 Million - $57.6 Million	643,986 Added 38.91%	2,298,890 $197 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $12.2 Million - $13.9 Million	204,161 Added 14.07%	1,654,904 $102 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $26.2 Million - $29.5 Million	453,213 Added 45.43%	1,450,743 $89.7 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $19.5 Million - $24.4 Million	335,895 Added 50.77%	997,530 $59.3 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $18.1 Million - $20.5 Million	278,407 Added 72.65%	661,635 $48 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $10.2 Million - $11 Million	-151,229 Reduced 28.3%	383,228 $26.8 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $45.6 Million - $49.8 Million	-717,941 Reduced 57.33%	534,457 $36.8 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $1.81 Million - $2.06 Million	30,087 Added 2.46%	1,252,398 $80.9 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $441,530 - $503,102	7,794 Added 0.64%	1,222,311 $71.2 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $11 Million - $13.8 Million	176,817 Added 17.04%	1,214,517 $76.7 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $33.3 Million - $38.7 Million	460,474 Added 79.77%	1,037,700 $79.8 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $95.7 Million - $123 Million	-1,527,638 Reduced 72.58%	577,226 $43.2 Million
Q4 2019 Feb 18, 2020	SELL	$61.62 - $67.78 $31 Million - $34.1 Million	-502,571 Reduced 19.27%	2,104,864 $137 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $55 Million - $60.7 Million	-879,926 Reduced 25.23%	2,607,435 $165 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $39.1 Million - $43.8 Million	-631,906 Reduced 15.34%	3,487,361 $236 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $11.9 Million - $13.3 Million	189,698 Added 4.83%	4,119,267 $268 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $45.1 Million - $58.8 Million	744,177 Added 23.36%	3,929,569 $246 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $67.7 Million - $74.9 Million	949,348 Added 42.46%	3,185,392 $246 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $6.77 Million - $7.9 Million	104,335 Added 4.89%	2,236,044 $158 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $155 Million - $189 Million	2,131,709 New	2,131,709 $161 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account